T. Rowe Price Investment Management, Inc. Crispr Therapeutics Ag Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,811,708 shares of CRSP stock, worth $178 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
3,811,708
Previous 2,737,470
39.24%
Holding current value
$178 Million
Previous $129 Million
16.66%
% of portfolio
0.09%
Previous 0.08%
Shares
10 transactions
Others Institutions Holding CRSP
# of Institutions
485Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$418 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$407 Million0.07% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$129 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$128 Million1.21% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$128 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.63B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....